Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Pattern of Use of Bevacizumab or Cetuximab in Patients With Metastatic Colorectal Cancer When Added to FOLFIRI Regimen as First-line Treatment; Multicenter, Registry Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03286738

Enrollment

1800

Registered

2017-09-18

Start date

2015-11-30

Completion date

2021-12-31

Last updated

2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Brief summary

* Registry * Multicenter, prospective observational study * Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Interventions

DRUGFOLFIRI, target agent

* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab * Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment 2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection®

Exclusion criteria

1\) Patients with conditions in which any study drug is contraindicated per the respective approved label.

Design outcomes

Primary

Measure	Time frame
percentage of use FOLFIRI regimen and target agents	through study completion, 3 years

Countries

South Korea

Contacts

Primary ContactJoong Bae Ahn

82-2-2228-8134

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026